HealthQuill Competition and Markets Authority
Antitrust regulators in the UK have cleared a $3.1 billion acquisition of Olink Holding AB by Thermo Fisher Scientific Inc., following an initial probe that began in May last year.
Drugs Medical Pharma

Thermo Fisher’s $3.1 billion buy of Olink gets UK competition regulators’ nod

Antitrust regulators in the UK have cleared a $3.1 billion acquisition of Olink Holding AB by Thermo Fisher Scientific Inc., following an initial.

Read More
Britain’s Competition and Markets Authority (CMA) expressed concerns over Theramex's planned acquisition of Femoston and Duphaston stating it may reduce competition and choice for hormone replacement therapy (HRT) treatments in the country.
Drugs Health Pharma

Britain’s CMA raises concern over Theramex’s Femoston buy

HQ Team April 4, 2024: Britain’s Competition and Markets Authority (CMA) expressed concerns over Theramex’s planned acquisition of Femoston and Duphaston stating it.

Read More
The UK’s competition regulator, Competition and Markets Authority has provisionally cleared UnitedHealth’s proposed £1.2bn ($1.6 billion) plan to buy EMIS after a probe by an independent panel.
Drugs Health Pharma

UK’s antitrust body provisionally clears $1.6b UnitedHealth-EMIS merger

HQ Team August 11, 2023: The UK’s competition regulator, Competition and Markets Authority has provisionally cleared UnitedHealth’s proposed £1.2bn ($1.6 billion) plan to.

Read More